Ciphergen reports biomarkers of Alzheimer's disease

By Elaine Rigoli

Tampa, Fla., July 18 - Ciphergen Biosystems, Inc. announced results of a multi-site study aimed at discovering and validating biomarkers for Alzheimer's disease. For biomarker discovery, cerebrospinal fluid (CSF) samples were analyzed from 65 Alzheimer's disease patients and 44 controls.

"We are pleased with the results of this multi-site study. These results may form the basis for potential diagnostic tests, and may provide tools to assist in the development of novel therapeutic agents for this devastating disease," president and chief executive officer Gail S. Page said in a news release.

Thirty peaks were identified with p<.01 between the disease and control group, and logistic regression was used to generate a panel comprising five proteins that had 92% sensitivity and 98% specificity, the release said.

The panel was tested on an independent set of 30 Alzheimer's disease samples and 29 controls, resulting in 97% sensitivity and 97% specificity.

Based in Fremont, Calif., Ciphergen develops a family of ProteinChip systems and services for clinical, research and process proteomics applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.